- Author
-
A.S. van Velzen
- Title
- INSIGHT in risk factors and treatment of inhibitors in nonsevere hemophilia A
- Supervisors
-
T.W. Kuijpers
C.J. Fijnvandraat - Co-supervisors
-
M. Peters
- Award date
- 7 July 2016
- Number of pages
- 287
- ISBN
- 9789491602610
- Document type
- PhD thesis
- Faculty
- Faculty of Medicine (AMC-UvA)
- Abstract
-
Hemophilia A is an inherited X-linked bleeding disorder that occurs in male offspring of carrier females. In these individuals a mutation in the F8 gene, located on the X-chromosome, causes a deficiency of the factor VIII protein, clotting factor VIII.
The worldwide prevalence of hemophilia is 1 in 5000 live male births, with one-third of the patients affected by severe hemophilia A and two-thirds of the patients have nonsevere disease.
In patients with hemophilia A there is an impaired hemostasis due to a reduction of their factor VIII plasma level. This is associated with clinical symptoms of spontaneous bleeds in joints and muscles.
An extremely severe and challenging complication of treatment with factor VIII concentrates in hemophilia A patients is the development of anti-factor VIII antibodies that inhibit (neutralize) the factor VIII activity, also referred to as inhibitors. This complication occurs in 25-30% of the severe hemophilia patients. Inhibitors seem to occur less frequently in nonsevere hemophilia A patients, although studies on inhibitor incidence in this group of patients are scarce.
When a nonsevere hemophilia A patient develops an inhibitor, the phenotype of the disease may change dramatically. Nonsevere haemophilia A patients would normally only experience incidental bleeding episodes, but after inhibitor development the bleeding phenotype may aggravate dramatically, especially if the inhibitor reduces the endogenous factor VIII plasma levels. This is associated with an increased morbidity and mortality.
This thesis focuses on the risk factors and treatment of inhibitors in nonsevere hemophilia A. - Note
- Research conducted at: Universiteit van Amsterdam
- Persistent Identifier
- https://hdl.handle.net/11245/1.536236
- Downloads
-
Thesis (complete)
Front matter
Chapter 1: General introduction and outline of the thesis
Chapter 2: Variation in baseline factor VIII concentration in a retrospective cohort of mild and moderate hemophilia A patients carrying the same F8 mutation
Chapter 3: Inhibitor development and mortality in nonsevere hemophilia A
Chapter 4: Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A
Chapter 5: Intensity of factor VIII treatment and the development of inhibitors in nonsevere hemophilia A patients: results of the INSIGHT case-control study
Chapter 6: Product type and the risk of inhibitor development in nonsevere hemophilia A patients
Chapter 7: The role of von Willebrand factor in the successful outcome of immune tolerance therapy in patients with severe hemophilia A with factor VIII inhibiting antibodies
Chapter 8: Inhibitors in nonsevere hemophilia A: outcome and eradication strategies
Chapter 9: The incidence and treatment of bleeding episodes in nonsevere hemophilia A patients with inhibitors
Chapter 10: Summary, general discussion
Appendices
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library, or send a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.